Emerging MF Treatment
Novel Emerging Investigational Treatment Strategies for Patients With Myelofibrosis

Released: November 30, 2023

Activity

Progress
1
Course Completed

In this episode, Jacqueline S. Garcia, MD, discusses novel agents and strategies in clinical trial development for treating patients with myelofibrosis, including:

  • Navitoclax (BCL-XL/BCL-2 inhibitor)
  • Pelabresib (BET inhibitor)
  • Imetelstat (telomerase inhibitor)
  • Luspatercept (erythroid maturation agent)
  • Additional strategies